Compare Regeneron Pharmaceuticals Inc (REGN) vs ProShares UltraPro QQQ ETF (TQQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs ProShares UltraPro QQQ ETF — how do they compare? Regeneron Pharmaceuticals Inc trades at $807.6 (market cap $83.43B), while ProShares UltraPro QQQ ETF trades at $71.61. The key difference: Regeneron Pharmaceuticals Inc pays a 0.46% dividend while ProShares UltraPro QQQ ETF pays none, and Regeneron Pharmaceuticals Inc is trading nearer its 52-week high, ProShares UltraPro QQQ ETF nearer its low. Which is the better fit depends on your goals.
| REGN | TQQQ | |
|---|---|---|
Market Cap | $83.43B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $852.03 | $87.22 |
52-Week Low | $555.51 | $37.89 |
Enterprise Value | $78.14B | — |
Dividend Yield | 0.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.
Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.
TQQQ, a 3x leveraged ETF tracking the Nasdaq-100, trades at $72.16, down 0.29% on the day. Technical indicators show a bullish trend with strong moving average support, while oscillators are neutral. Recent news highlights its amplified returns during the AI boom but warns of structural costs like volatility decay. The ETF's performance is closely tied to large-cap tech earnings and market sentiment.
The outlook for TQQQ hinges on continued tech sector strength, particularly AI-driven growth, but risks include high volatility and decay from daily rebalancing. Investors face amplified gains or losses, making it suitable only for those comfortable with significant risk. Monitoring underlying index performance and tech earnings is critical for timing entries and exits.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About ProShares UltraPro QQQ ETF
TQQQ is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the Nasdaq-100 Index. It is one of the most liquid and actively traded instruments in the market, designed for sophisticated traders to amplify short-term bullish exposure to large-cap non-financial growth stocks, predominantly in the technology and communication sectors.
Read more on TQQQ →
